FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016090943> ?p ?o ?g. }

• W2016090943 endingPage "620" @default.
• W2016090943 startingPage "618" @default.
• W2016090943 abstract "The development of angiotensin converting enzyme inhibitors is often cited as a prime example of task oriented research. The truth is far from this, and, as so often, chance played a large part in the development of this group of drugs. Some 25 years ago a group of Brazilian pharmacologists was searching for substances that would block the inactivation of bradykinin, a process subsequently shown to take place in man in the pulmonary vascular bed. It was shown that this was also the site for the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, and the two processes were controlled by enzymes that, if not the same, were very similar. It has been appreciated for many years that the renin-angiotensin aldosterone system is important in the control of blood pressure. Most early stratagems to lower blood pressure clinically, however, were based on manipulating the sympathetic nervous system, and attempts to perturb the renin-angiotensin-aldosterone system came much later. The use of effective orally active angiotensin converting enzyme inhibitors depended on translating the experiences of pharmacologists, who were interested primarily in the breakdown of bradykinin, to physiologists, who were interested in the mechanisms of controlling blood pressure, and then using the skills of medicinal chemists and clinical pharmacologists to design and test suitable compounds. A recent review by Ferreira, an important figure in the early development of this subject, details this interesting story.1 There are currently two orally active angiotensin converting enzyme inhibitors available in the United Kingdom, captopril and enalapril. Some 20 compounds that have a similar pharmacological activity are in, various stages of development, several of them having been already given to volunteers and patients. This review will concentrate on the two marketed products because, as will be seen below, a risk-benefit analysis for angiotensin converting enzyme inhibitors can be made only after extensive exposure of patients, and any assessment of new members of the group is difficult. I will therefore compare captopril and enalapril with respect to their pharmacology, relative efficacy, and relative toxicity." @default.
• W2016090943 created "2016-06-24" @default.
• W2016090943 creator A5042765093 @default.
• W2016090943 date "1988-02-27" @default.
• W2016090943 modified "2023-09-24" @default.
• W2016090943 title "New Drugs: Angiotensin converting enzyme inhibitors" @default.
• W2016090943 cites W1978921236 @default.
• W2016090943 cites W1991581782 @default.
• W2016090943 cites W2028919494 @default.
• W2016090943 cites W2048228293 @default.
• W2016090943 cites W2079733906 @default.
• W2016090943 cites W2082923902 @default.
• W2016090943 cites W2092274208 @default.
• W2016090943 cites W2332694193 @default.
• W2016090943 cites W36184483 @default.
• W2016090943 cites W4245244523 @default.
• W2016090943 cites W4252698039 @default.
• W2016090943 doi "https://doi.org/10.1136/bmj.296.6622.618" @default.
• W2016090943 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2545245" @default.
• W2016090943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2832034" @default.
• W2016090943 hasPublicationYear "1988" @default.
• W2016090943 type Work @default.
• W2016090943 sameAs 2016090943 @default.
• W2016090943 citedByCount "23" @default.
• W2016090943 crossrefType "journal-article" @default.
• W2016090943 hasAuthorship W2016090943A5042765093 @default.
• W2016090943 hasBestOaLocation W20160909432 @default.
• W2016090943 hasConcept C126322002 @default.
• W2016090943 hasConcept C136764020 @default.
• W2016090943 hasConcept C181199279 @default.
• W2016090943 hasConcept C185592680 @default.
• W2016090943 hasConcept C198710026 @default.
• W2016090943 hasConcept C2522767166 @default.
• W2016090943 hasConcept C27016395 @default.
• W2016090943 hasConcept C41008148 @default.
• W2016090943 hasConcept C55493867 @default.
• W2016090943 hasConcept C71924100 @default.
• W2016090943 hasConcept C84393581 @default.
• W2016090943 hasConcept C98274493 @default.
• W2016090943 hasConceptScore W2016090943C126322002 @default.
• W2016090943 hasConceptScore W2016090943C136764020 @default.
• W2016090943 hasConceptScore W2016090943C181199279 @default.
• W2016090943 hasConceptScore W2016090943C185592680 @default.
• W2016090943 hasConceptScore W2016090943C198710026 @default.
• W2016090943 hasConceptScore W2016090943C2522767166 @default.
• W2016090943 hasConceptScore W2016090943C27016395 @default.
• W2016090943 hasConceptScore W2016090943C41008148 @default.
• W2016090943 hasConceptScore W2016090943C55493867 @default.
• W2016090943 hasConceptScore W2016090943C71924100 @default.
• W2016090943 hasConceptScore W2016090943C84393581 @default.
• W2016090943 hasConceptScore W2016090943C98274493 @default.
• W2016090943 hasIssue "6622" @default.
• W2016090943 hasLocation W20160909431 @default.
• W2016090943 hasLocation W20160909432 @default.
• W2016090943 hasLocation W20160909433 @default.
• W2016090943 hasLocation W20160909434 @default.
• W2016090943 hasOpenAccess W2016090943 @default.
• W2016090943 hasPrimaryLocation W20160909431 @default.
• W2016090943 hasRelatedWork W1517578770 @default.
• W2016090943 hasRelatedWork W1977161870 @default.
• W2016090943 hasRelatedWork W1983513268 @default.
• W2016090943 hasRelatedWork W2011705357 @default.
• W2016090943 hasRelatedWork W2045675210 @default.
• W2016090943 hasRelatedWork W2051455432 @default.
• W2016090943 hasRelatedWork W2323581027 @default.
• W2016090943 hasRelatedWork W2748952813 @default.
• W2016090943 hasRelatedWork W282211751 @default.
• W2016090943 hasRelatedWork W2899084033 @default.
• W2016090943 hasVolume "296" @default.
• W2016090943 isParatext "false" @default.
• W2016090943 isRetracted "false" @default.
• W2016090943 magId "2016090943" @default.
• W2016090943 workType "article" @default.